Cycle on Aug 13, 2026

I will start by checking the open threads and watches for this topic using the `list_threads` tool to see what past cycles have flagged for follow-up or monitoring.

I will search the web for major science and health news from the past week, sorting by recency, to see what significant events, trial readouts, or policy shifts have occurred.

I see some highly relevant recent news items here! 1. "FDA approves Replimune's Tudriqev (RP1) for advanced melanoma..." This corresponds to one of our watches: `Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma` (though that watch is for the phase 3 confirmatory trial results, the approval itself has just happened!). Let's search for this to see if the FDA has just approved Tudriqev (RP1) in advanced melanoma. 2. "In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment (Endpoints)" -> ITM radiopharma therapy. Let's look up "FDA rejects ITM radiopharma therapy" or similar. 3. "NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo..." 4. Let's also check our watch list: - "CARDIO-TTRansform full dataset presentation at ESC Congress 2026" - expected late August 2026. Wait, today is August 13, 2026. Let's search if any early data or abstracts have dropped, or other updates. - "FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy" - expected after the July 29, 2026 CTGTAC advisory committee meeting. Let's search for "Capricor deramiocel FDA" or "deramiocel FDA approval". - "Nancy Grace Roman Space Telescope" launch scheduled for August 30, 2026. Let's check status. - "FDA response to CRL public disclosure citizen petition" - docket FDA-2026-P-4369. Let's search for this. - Let's do a general search for "FDA approval" and "clinical trial" with `sort="recent"` and `freshness="week"`. Let's run a search for "Replimune Tudriqev RP1 FDA approval" to get details on the approval.

This is an incredibly rich update on Replimune's Tudriqev (RP1). Let's review the details: - FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), formerly RP1, in combination with nivolumab (Opdivo) on August 6, 2026. - It is indicated for adults with unresectable advanced cutaneous melanoma who progressed on an anti-PD-1 antibody-based regimen. - This is the first FDA approval of an oncolytic virus therapy since Amgen's T-VEC in 2015! - It followed an intense regulatory path: two prior CRLs (July 22, 2025, and April 10, 2026). - An FDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting on July 30, 2026, voted 10-3 in favor of the drug's efficacy data being evaluable and clinically meaningful, which paved the way for the accelerated approval on August 6, 2026 (just 4 days after the August 2, 2026 target action date). - We have a watch related to this: `Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma` (expected late 2027), which is required to support the accelerated approval. We should keep that watch active since it's about the Phase 3 confirmatory trial results, but we can write a finding about the accelerated approval of Tudriqev. Let's look at the other lead: "In surprise decision, FDA rejects ITM radiopharma therapy expected to rival Novartis treatment (Endpoints)" Let's search for "FDA rejects ITM radiopharma therapy" or "ITM radiopharma FDA CRL" or similar.

Excellent. Let's fetch the press release or a detailed article on ITM's CRL to get precise details. I'll fetch `https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-receives-complete-response-letter-for-177lu-edotreotide-itm-11-763/` or `https://www.biospace.com/fda/fda-rejects-itm-isotopes-radiopharma-therapy-over-manufacturing-issues`. Let's fetch the ITM press release first.

This is excellent! The FDA rejected ITM's 177Lu-edotreotide (ITM-11) for GEP-NETs on August 7, 2026. This was a surprise decision, but importantly, it did NOT cite safety or efficacy issues, only Chemistry, Manufacturing, and Controls (CMC) and third-party commercial facility inspection-related items. The COMPETE trial data package stands. This would have competed with Novartis's Lutathera. Let's look for other major health/science news. Is there any news on: - Capricor's deramiocel BLA? (Expected after July 29, 2026 CTGTAC meeting). Let's search "Capricor deramiocel FDA". - Saol Therapeutics SL1009? - CARDIO-TTRansform trial of Wainua (eplontersen) in ATTR-CM? - Nancy Grace Roman Space Telescope (launch planned for August 30, 2026)? - Vera Therapeutics ORIGIN 3 trial of Trutakna? - H5N1 bird flu transmission in Australia or New Zealand? - FDA CRL public disclosure policy (Docket FDA-2026-P-4369)? Let's search for "Capricor deramiocel FDA" first.

This is a huge development! Let's examine the details of the Capricor deramiocel BLA and advisory committee meeting: - On July 29, 2026, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 9-3 that Capricor had NOT shown substantial evidence of effectiveness for deramiocel (CAP-1002) in Duchenne muscular dystrophy (DMD) cardiomyopathy. - The buildup was dominated by a major dispute over the statistical analysis plan (SAP) of the Phase 3 HOPE-3 trial. The FDA reviewers published briefing documents showing that the trial "did not meet its pre-specified primary and secondary efficacy endpoints" under SAP version 1.1 (the initial pre-specified plan), showing no statistically significant difference between deramiocel and placebo at 12 months. - Capricor, however, claimed success under SAP version 3.0, which was finalized during the trial's open-label extension period before unblinding. Capricor's CEO Linda Marbán argued that the FDA post-hoc analyses relied on SAP version 1.1, which was an unsigned, incomplete internal draft. - The FDA also raised questions about the effectiveness of blinding in HOPE-3 due to distinct adverse event profiles (42% hypersensitivity in treatment vs 15% in placebo). - This negative AdCom vote (9-3 against) has severely damaged deramiocel's approval prospects ahead of its upcoming FDA PDUFA verdict on August 22, 2026. - This resolves our watch: `FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy` which was expected following the July 29, 2026 meeting (though the final PDUFA target action date is August 22, 2026, we should record the AdCom event and keep the watch active for the final August 22, 2026 decision). Wait, the watch title says "FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy" and the description says "expected following the July 29, 2026 CTGTAC advisory committee meeting." The fire date is 2026-08-31T00:00:00Z. So we should definitely record this event! Let's do that. Let's search for some other watches: 1. `CARDIO-TTRansform full dataset presentation at ESC Congress 2026` (Wainua/eplontersen in ATTR-CM, expected late August 2026). Let's search for "CARDIO-TTRansform ESC Congress 2026" or "eplontersen CARDIO-TTRansform". 2. `Nancy Grace Roman Space Telescope` launch scheduled for August 30, 2026. Let's search for "Nancy Grace Roman Space Telescope launch date August 2026". 3. `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` or `Australia H5N1 transmission to poultry or local wildlife`. Let's search for "H5N1 New Zealand" and "H5N1 Australia" to see if there are any recent updates. 4. `Sobi BLA resubmission for NASP in uncontrolled gout` or `Achieve Life Sciences NDA resubmission for cytisinicline`. Let's search for these. 5. `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` (expected Q3 2026). Let's search "Vera Therapeutics ORIGIN 3". 6. `FDA response to CRL public disclosure citizen petition (Docket FDA-2026-P-4369)`. Let's search "FDA-2026-P-4369" or "CRL public disclosure citizen petition". Let's do a search on CARDIO-TTRansform.

This is a very important update on CARDIO-TTRansform! - In July 2026, AstraZeneca and Ionis announced that the Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) in ATTR-CM *missed* its primary composite endpoint of cardiovascular mortality and recurrent cardiovascular clinical events up to Week 140 compared with placebo in the overall population. - The reason is that most participants were already on contemporary standard-of-care (a transthyretin stabilizer, like Pfizer's Vyndaqel/tafamidis or BridgeBio's Attruby/acoramidis), and adding eplontersen on top did not provide a statistically significant benefit. - However, there was a prespecified subgroup analysis of patients receiving eplontersen as *monotherapy* (not on background stabilizers) which demonstrated nominal significance. - The full dataset presentation is scheduled for Hot Line 1 at the ESC Congress on August 28, 2026. This will show the full findings, subgroup analyses (including the monotherapy subgroup and combination subgroup), and a meta-analysis study. - This represents a massive shift in the ATTR-CM field, causing ripple effects for Alnylam (Amvuttra) and BridgeBio (Attruby). - This is a direct development on our watch: `CARDIO-TTRansform full dataset presentation at ESC Congress 2026` (scheduled for August 28, 2026). Let's keep this watch open since the presentation is on August 28 (about two weeks from today, August 13, 2026). But we should write a note updating our findings on ATTR-CM, or let's see if we have an existing finding for this. Checking prior findings: we have `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance`, `amgen-tavneos-regulatory-crisis-advocate-retraction`, `hhs-clinical-trials-reform-operation-trailblazer`, `fda-crl-public-disclosure-policy`. We don't have an existing finding on ATTR-CM, so we can write a fresh one! Let's check other watches. Let's search for "Nancy Grace Roman Space Telescope launch date August 2026" or similar.

This is another massive update! - The Nancy Grace Roman Space Telescope is on track for launch on **August 30, 2026** at 7:26 a.m. EDT (11:26 UTC) aboard a SpaceX Falcon Heavy rocket from Launch Complex 39A at NASA's Kennedy Space Center in Florida. - This is nine months ahead of schedule! - NASA is currently integrating the telescope with SpaceX hardware. - It will travel to the Sun-Earth Lagrange point 2 (L2), 1.5 million km from Earth, to study dark energy, dark matter, and exoplanets with a field of view 100 times larger than Hubble's. - This directly relates to our watch: `Launch of NASA's Nancy Grace Roman Space Telescope` (August 30, 2026). The watch is set to fire on August 30, 2026, so we'll keep it open but we should definitely write a note or update details. Let's check if there are other updates. Let's search for "H5N1 New Zealand" and "H5N1 Australia" to see if there's any current status.

Wow, look at these details on H5N1 in Australia and New Zealand! This is highly critical: - On July 29, 2026, Australia confirmed its first local transmission of H5N1 bird flu in its native bird population, specifically among greater crested terns in South Australia. - More recently, on August 3, 2026, Australia warned that H5N1 was likely to spread further after its first mass mortality episode among seabirds, which killed about 50 greater crested terns off the Cape Jaffa coast (south of Adelaide). In total, Julie Collins (Minister for Agriculture, Fisheries and Forestry) confirmed H5N1 in a group of 49 dead and 35 sick terns. - In New Zealand, H5N1 was detected for the first time in a migratory brown skua seabird on a beach near Wellington, which was reported around July 15-16, 2026. - New Zealand has started vaccinating endangered species and is requiring biosecurity plans from the poultry sector. - Currently, there is no evidence of mass wildlife deaths or transmission between wild birds in New Zealand. - This relates to two of our watches: 1. `Australia H5N1 transmission to poultry or local wildlife` (cardinality: ongoing) - This has fired! Local transmission between greater crested terns (local wildlife) in South Australia was confirmed on July 29, 2026, and a mass mortality episode of terns was confirmed on August 3, 2026. This is a very significant outcome. I will call `record_event` on this watch with `resolves: false` (since it is ongoing, we want to keep tracking if it spreads to poultry or marine mammals). 2. `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (cardinality: ongoing) - The first case in NZ was a migratory brown skua, but there is "no evidence of any mass mortality in wildlife or transmission between wild birds in New Zealand" yet. So this watch has not fired yet. Let's check if there are any other watches we can resolve or update. Let's search for "Vera Therapeutics ORIGIN 3" or "Trutakna IgA nephropathy eGFR".

This is fantastic information! - Vera Therapeutics received FDA accelerated approval for **TRUTAKNA (atacicept-vymj)** as the first dual BAFF/APRIL inhibitor for IgA nephropathy (IgAN) on **July 7, 2026**. - The approval was based on a prespecified interim analysis of the Phase 3 ORIGIN 3 trial, where patients treated with Trutakna achieved a 46% reduction from baseline in proteinuria, showing a statistically significant and clinically meaningful 42% reduction compared to placebo at week 36. - To support full approval, Vera aligned with the FDA on an earlier ORIGIN 3 final efficacy analysis of estimated glomerular filtration rate (eGFR) kidney function data, with results expected in **Q3 2026** (this quarter!). - This is a direct update on our watch: `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` (expected Q3 2026). The watch is for the confirmatory eGFR results, which are expected in Q3 2026, so we'll keep it active since they haven't dropped yet, but we have a huge update on the accelerated approval of Trutakna in July 2026. Let's do a search on the FDA Complete Response Letter public disclosure policy (Docket FDA-2026-P-4369) to see if there are any updates there. This is a very interesting policy angle!

The search did not yield specific hits for "Docket FDA-2026-P-4369". Let's broaden the query to "FDA Complete Response Letter public disclosure policy" or "FDA citizen petition Complete Response Letters" and see what comes up.

Let's fetch `https://www.biospace.com/fda/fda-freezes-crl-trove-as-radical-transparency-push-hits-speedbump` or `https://www.biospace.com/fda/fdas-radical-transparency-policy-for-rejections-runs-into-legal-uncertainty` to see what exactly happened with the CRL transparency policy. Let's fetch the "FDA does not freeze CRL trove" article.

Ah, that fetch failed due to a timeout. Let's try fetching `https://www.pharmavoice.com/news/whats-in-the-fdas-latest-batch-of-rejection-letters/825923/` instead, or we can fetch the STAT news or Biospace article again or try another source. Let's try `https://www.biospace.com/fda/fdas-radical-transparency-policy-for-rejections-runs-into-legal-uncertainty`.

This is extremely clear and gives us everything we need. The search budget is spent, so let's summarize and write up the findings we've gathered! Let's review the findings we want to write: 1. **Replimune's Tudriqev (RP1) Accelerated Approval in Advanced Melanoma**: - On August 6, 2026, the FDA granted accelerated approval to Replimune's Tudriqev (vusolimogene oderparepvec-wtpg; RP1) in combination with nivolumab (Opdivo) for adults with unresectable advanced cutaneous melanoma who progressed on an anti-PD-1 antibody-based regimen. - This represents the first oncolytic virus therapy approved by the FDA since Amgen's T-VEC in 2015. - It capped a dramatic regulatory battle: two prior CRLs (July 2025 and April 2026) and a July 30, 2026, FDA advisory committee (CTGTAC) meeting where members voted 10-3 that the drug's efficacy data were evaluable and clinically meaningful. - Continued approval is contingent on verification of clinical benefit in a confirmatory trial (the Phase 3 IGNYTE-3 trial, which we are tracking via watch `019feddb-a316-76c7-beeb-a199a4b65d4b`). - We should write a new finding on this! Let's name the slug `replimune-tudriqev-melanoma-fda-approval`. Let's check if there is an existing finding. No, the closest prior finding is `amgen-tavneos-regulatory-crisis-advocate-retraction` or `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance`. So `replimune-tudriqev-melanoma-fda-approval` is a great new slug. 2. **FDA Rejects ITM's Radiopharmaceutical ITM-11 (177Lu-edotreotide)**: - On August 7, 2026, the FDA issued a Complete Response Letter (CRL) rejecting ITM Isotope Technologies Munich's 177Lu-edotreotide (ITM-11) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). - This was a surprise rejection for a highly anticipated competitor to Novartis's blockbuster Lutathera. - Crucially, the CRL did *not* cite any concerns with clinical safety or efficacy (the pivotal COMPETE trial data stands), but instead focused on Chemistry, Manufacturing, and Controls (CMC) and third-party commercial facility inspection-related items. ITM plans to work with the FDA and resubmit. - This is a new finding. Let's use the slug `itm-radiopharma-itm11-fda-rejection`. 3. **Capricor's Deramiocel Faces Regulatory Jeopardy After Negative AdCom Vote**: - On July 29, 2026, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 9-3 against recommending approval for Capricor Therapeutics' deramiocel (CAP-1002) in Duchenne muscular dystrophy (DMD) cardiomyopathy, stating that the company had not shown "substantial evidence" of effectiveness. - The meeting was dominated by a fierce statistical dispute. The FDA briefing documents revealed that the Phase 3 HOPE-3 trial did *not* meet its pre-specified primary and secondary endpoints under the original Statistical Analysis Plan (SAP version 1.1). Capricor claimed success under SAP version 3.0, which was finalized during the trial's open-label extension before unblinding. The FDA also questioned blinding integrity due to a high rate of hypersensitivity reactions in the treatment group (42% vs 15%). - This represents a massive setback ahead of the August 22, 2026 PDUFA target action date. - This is a new finding. Let's use the slug `capricor-deramiocel-dmd-negative-adcom`. 4. **Vera Therapeutics Wins FDA Accelerated Approval for Trutakna in IgA Nephropathy**: - On July 7, 2026, the FDA granted accelerated approval to Vera Therapeutics' Trutakna (atacicept-vymj) as the first dual BAFF/APRIL inhibitor for adults with primary IgA nephropathy (IgAN) at risk of disease progression. - The approval was supported by a prespecified interim analysis of the Phase 3 ORIGIN 3 trial, demonstrating a 46% reduction in proteinuria from baseline (a 42% reduction relative to placebo) at week 36. - Vera has aligned with the FDA on an earlier final efficacy analysis of estimated glomerular filtration rate (eGFR) kidney function data from ORIGIN 3, with results expected in Q3 2026 to support potential full approval. - This is a new finding. Let's use the slug `vera-therapeutics-trutakna-igan-fda-approval`. 5. **AstraZeneca and Ionis's Eplontersen (Wainua) Misses Phase 3 ATTR-CM Endpoint**: - In July 2026, AstraZeneca and Ionis announced that the Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) *missed* its primary composite endpoint of cardiovascular mortality and recurrent cardiovascular clinical events up to week 140 compared with placebo in the overall population. - The failure is attributed to high background use of contemporary standard-of-care stabilizers (like Pfizer's Vyndaqel/tafamidis or BridgeBio's Attruby/acoramidis), which diluted eplontersen's treatment effect when added on top. - However, a prespecified subgroup analysis of eplontersen as *monotherapy* demonstrated nominal significance, offering a sliver of hope. - The full dataset and subgroup analyses will be presented at the European Society of Cardiology (ESC) Congress on August 28, 2026, which will be highly scrutinized to see how gene silencers fit into the evolving ATTR-CM treatment landscape. - This is a new finding. Let's use the slug `eplontersen-cardio-ttransform-trial-failure`. 6. **FDA Resumes Controversial Complete Response Letter Transparency Policy After Three-Month Pause**: - Wait! We have an existing prior finding on this: `fda-crl-public-disclosure-policy`. Let's review it. Its title is "FDA Resumes Controversial Complete Response Letter Transparency Policy After Three-Month Pause". - Let's read the notes first to make sure we have the exact prior content, so we can update it in place. I will call `read_notes` to see the text of `fda-crl-public-disclosure-policy`. Let's do that.

Ah! We have some existing notes that are very relevant: - `capricor-deramiocel-dmd-cardiomyopathy-regulatory-path` (updated 2026-08-10): "FDA Advisory Committee Votes 9-3 Against Capricor's Deramiocel in DMD Cardiomyopathy" - `replimune-tudriqev-melanoma-fda-approval` (updated 2026-08-12): "FDA Grants Accelerated Approval to Replimune's TUDRIQEV (RP1) in Advanced Melanoma" - `astrazeneca-ionis-wainua-cardio-ttransform-phase3-failure` (updated 2026-08-12): "AstraZeneca and Ionis' Wainua Fails Phase 3 CARDIO-TTRansform Trial in ATTR-CM" - `vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval` (updated 2026-08-13): "Vera Therapeutics' Trutakna Wins Accelerated FDA Approval, Positioning for Critical Q3 eGFR Confirmatory Test" - `h5n1-bird-flu-arrival-australia-new-zealand` or `h5n1-bird-flu-australia-new-zealand-wildlife-threat` (updated 2026-08-12) or `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` (updated 2026-08-11). Since these notes are already written and updated very recently, we should check if there are any *new* details we need to add or if we should write a new finding for the ITM radiopharmaceutical rejection (since that happened on August 7, 2026, and is not in our notes list). Let's see: ITM-11 was rejected on August 7, 2026. This is a brand new event that happened in the past week! Also, let's look at the H5N1 situation. Our note `h5n1-bird-flu-australia-new-zealand-wildlife-threat` was updated on August 12, 2026. Let's see if there is any other new development or if we should write a note on ITM. Yes, we should definitely write a finding for ITM's rejection because it is a major event that happened on August 7, 2026 (announced August 10, 2026) and is highly consequential for the radiopharmaceutical space. Let's check if we can resolve any threads. Let's look at the active threads again: - `FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy` (watch, fire_date 2026-08-31) - The final regulatory decision is still pending (August 22, 2026), but we have the AdCom vote (9-3 against) recorded. Wait! The watch is for the "FDA's final regulatory decision (approval or complete response letter)". So it hasn't fired yet since the FDA hasn't made the final decision. The final decision is expected on or before August 22, 2026. So we should keep this watch active. - `Australia H5N1 transmission to poultry or local wildlife` (watch, ongoing) - Wait, we had a watch for Australia H5N1 transmission to poultry or local wildlife. Let's check its details: "Monitor whether the newly arrived H5N1 avian influenza strain jumps from migratory seabirds to local Australian wildlife, marine mammals (e.g. fur seals), or commercial poultry farms." Has it jumped to local Australian wildlife? Yes! On July 29, 2026, Julie Collins confirmed local transmission between greater crested terns (local wildlife) in South Australia, and on August 3, 2026, a mass mortality episode of 50 greater crested terns was confirmed. So this watch has fired! Let's record this event. - Let's check the watch `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (watch, ongoing). In New Zealand, H5N1 was detected in a brown skua (migratory seabird) but there is no evidence of mass wildlife deaths or transmission between wild birds yet. So this has not fired. - Let's check the watch `Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma` (watch, fire_date 2027-12-31). This is for the Phase 3 confirmatory trial results, which are expected in late 2027, so it hasn't fired. - Let's check `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` (watch, fire_date 2026-09-30). This is for the eGFR confirmatory results, expected in Q3 2026, so it hasn't fired yet. Let's record the event for `Australia H5N1 transmission to poultry or local wildlife`! Its thread ID is `019f2f50-7f4d-7361-8f05-cdf170c2d727`. Let's check if that's correct. Yes, looking at the list of threads: `id: '019f2f50-7f4d-7361-8f05-cdf170c2d727', kind: 'watch', title: 'Australia H5N1 transmission to poultry or local wildlife'` Let's call `record_event` on it. Since it's an `ongoing` watch, we should pass `resolves: false` to keep it active for tracking poultry or marine mammal transmission. Let's do that.

Excellent! Now let's write the new finding for the FDA rejection of ITM's radiopharmaceutical ITM-11 (177Lu-edotreotide). Let's see: what slug should we use? We can use `itm-radiopharma-itm11-fda-crl` or `itm-radiopharma-itm11-fda-rejection`. Let's use `itm-radiopharma-itm11-fda-rejection`. Let's make sure the note has the required format: - No YAML frontmatter. - Title is the first `# ` heading. - Grounded in concrete evidence with 1-2 verbatim quotes kept with their links. - Uses stable slug. Let's compose the note. The title: `# FDA Rejects ITM’s Radiopharmaceutical ITM-11 Over Manufacturing and Third-Party Facility Deficiencies` We will cite: - [ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11)](https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-receives-complete-response-letter-for-177lu-edotreotide-itm-11-763/) - ITM Isotope Technologies Munich, August 10, 2026. - [FDA's radical transparency policy for rejections runs into legal uncertainty](https://www.biospace.com/fda/fdas-radical-transparency-policy-for-rejections-runs-into-legal-uncertainty) - BioSpace, July 20, 2026. Let's draft the body of the note: On August 7, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding ITM Isotope Technologies Munich SE’s (ITM) New Drug Application (NDA) for **177Lu-edotreotide (ITM-11)**, an investigational targeted radiotherapeutic for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The decision was a major surprise for the radiopharmaceutical sector, as ITM-11 was highly anticipated as a key competitor to Novartis’s blockbuster Lutathera. Importantly, the FDA did not raise any concerns regarding the clinical or nonclinical efficacy and safety data of ITM-11, leaving the pivotal Phase 3 COMPETE trial package fully intact. Instead, the rejection was entirely driven by Chemistry, Manufacturing, and Controls (CMC) issues and third-party commercial facility inspection findings. ITM has expressed confidence in the therapeutic potential of ITM-11 and stated its intention to address the regulatory feedback and resubmit the NDA. Let's call `write_note` for this finding.

Excellent! The note has been written successfully. Let's check if we should register any watches for this. Yes, we should register a watch to monitor ITM's resubmission of the ITM-11 NDA following the resolution of the CMC and third-party facility deficiencies. This is very similar to our other CMC-related watches. Let's call `record_watch` for this. Title: `ITM NDA resubmission for ITM-11 in GEP-NETs` Description: `Monitor ITM's resubmission of its NDA for ITM-11 to the FDA following the resolution of the CMC and third-party commercial facility deficiencies cited in the August 2026 CRL.` Entity: `ITM Isotope Technologies Munich` Watch type: `tripwire` Cardinality: `one_shot` Let's do that!

Perfect! The watch has been successfully registered. Let's double-check if there are any other actions required. 1. Did we write a note/finding? Yes, `itm-radiopharma-itm11-fda-rejection`. 2. Did we check existing threads/watches? Yes, we called `list_threads` and recorded an event on `Australia H5N1 transmission to poultry or local wildlife` (it has fired for local wildlife transmission). 3. Did we register any new watches? Yes, we registered `ITM NDA resubmission for ITM-11 in GEP-NETs`. 4. Are there any other threads to resolve? Let's check: none of the other active threads have fully resolved yet (e.g. Capricor's final FDA decision is still pending on August 22, 2026; Nancy Grace Roman telescope launch is August 30, 2026; Vera eGFR results are Q3 2026; CARDIO-TTRansform full results are August 28, 2026). So they should all remain active. We are ready to call `finish_cycle`. Let's end the research cycle.

I have successfully conducted a thorough research cycle on the latest consequential science and health news, focusing on recent developments, regulatory outcomes, and updates to existing watches. ### Key Findings & Actions Completed This Cycle 1. **New Finding Logged: FDA Rejection of ITM's Radiopharmaceutical ITM-11 (`itm-radiopharma-itm11-fda-rejection`)** - On August 7, 2026, the FDA issued a Complete Response Letter (CRL) rejecting ITM Isotope Technologies Munich's NDA for **177Lu-edotreotide (ITM-11)** for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). - This was a surprise decision in a highly anticipated race to challenge Novartis's blockbuster Lutathera. - Crucially, the CRL did *not* cite any concerns with clinical safety or efficacy—the pivotal Phase 3 COMPETE trial data package stands—but focused exclusively on Chemistry, Manufacturing, and Controls (CMC) and third-party commercial facility inspection-related items. - A new **one-shot watch** has been registered to track ITM's resubmission of the NDA following the resolution of these manufacturing deficiencies. 2. **Watch Event Recorded: Australia Confirms H5N1 Local Wildlife Transmission and Mass Mortality** - An event was recorded on the ongoing watch `Australia H5N1 transmission to poultry or local wildlife` (`019f2f50-7f4d-7361-8f05-cdf170c2d727`). - On July 29, 2026, Australia confirmed its first local transmission of H5N1 bird flu (clade 2.3.4.4b) in native wildlife among greater crested terns in South Australia. - On August 3, 2026, the country reported its first mass mortality episode of native wildlife, confirming H5N1 in a cluster of 49 dead and 35 sick terns off the coast of Cape Jaffa. - The watch remains active to track potential transmission into commercial poultry flocks or marine mammals. 3. **Status Check on Active Watches** - **Capricor's Deramiocel BLA (`capricor-deramiocel-dmd-cardiomyopathy-regulatory-path`):** The BLA faces severe regulatory hurdles following a highly contentious 9-3 negative vote by the FDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) on July 29, 2026, over statistical analysis discrepancies in the Phase 3 HOPE-3 trial. The final PDUFA target action date is August 22, 2026. - **AstraZeneca/Ionis's Eplontersen (`astrazeneca-ionis-wainua-cardio-ttransform-phase3-failure`):** Following the July announcement that the Phase 3 CARDIO-TTRansform trial missed its primary composite endpoint in the overall ATTR-CM population, all eyes are on the full dataset presentation at the ESC Congress Hot Line session on August 28, 2026, to assess the monotherapy subgroup signal. - **Nancy Grace Roman Space Telescope (`019fb013-39c2-71d8-932b-66e49c963e6a`):** NASA's next great observatory is undergoing final SpaceX Falcon Heavy hardware integration and remains on track for an ahead-of-schedule launch on August 30, 2026. - **Vera Therapeutics' Trutakna (`vera-therapeutics-trutakna-atacicept-igan-fda-accelerated-approval`):** Following its accelerated approval on July 7, 2026, the company is preparing to release critical confirmatory eGFR kidney function data from the Phase 3 ORIGIN 3 trial in Q3 2026.